Amgen Inc. (NASDAQ: AMGN) makes Aranesp and Epogen, while Johnson & Johnson (NYSE: JNJ) makes Procrit, all used to help cancer and kidney disease patients overcome anemia. But now the FDA says these drug show greater risks for patients with certain cancers on tumor progression and survival, as well as blood clots. While both companies believe the risks were seen when the drugs were given for unapproved uses, including higher-than-recommended doses, it is possible that following the study, the FDA may recommend to end the use of these drugs for patients whose anemia is caused by cancer chemotherapy, or who are at greater risk, but still allow it for kidney disease patients.
Still, as some analysts believe, with the recent updates both companies had on product prescribing and labeling, it is unlikely the drugs will be completely inadvisable for use in cancer patients as they allow the cycle of chemotherapy to continue more smoothly, helping to strengthen them after each treatment. It is more likely the companies will work with the FDA for better regulation on these drugs.
On the news, Amgen shares fell nearly 2%, while JNJ shares climbed over 1%. Surprising? Not really.
Aranesp sales totaled $827 million in the fourth quarter, while sales of Epogen (marketed more to kidney disease patients) totaled to $638 million in the same period, together accounting for 40% of the $3.7 billion of the company's overall revenue. And these figures are already showing significant declines (25% and 3% respectively) over the year ago period as the drugs were tied to higher risks of heart attack, stroke and death at high doses.
Meanwhile, at Johnson & Johnson the situation isn't all that bad, as one can surmise from the stock reaction. The company had announced $61 billion in overall sales for 2007, of which about 40% was pharmaceutical. Procrit only had $1.69 billion in U.S. sales in 2007, an 18% drop from the previous year, but only accounting for less than 3% overall sales. I can only assume that worldwide sales of Procrit are at most double, still accounting for a relatively smaller portion of JNJ sales when compared to Amgen.
It is interesting to see the impact of this news on both companies and how diversification can be key, not only in one's personal portfolio, but in companies as well.
Before the bell: Futures climb as Wall Street eyes deals
Entrepreneur's Journal: Putting together a solid sales contract
The week in preview: Earnings from Walmart, Macy's, and other retailers
Reader Comments (Page 1 of 1)
3-11-2008 @ 10:27PM
MHL5723 said...
ALL THE DRUGS MGS ARE THE SAME, ALL OF THE DRUGS ARE SAFE, THEM ALL THE PEOPLE SAY HELP ME PLEASE HELP, AND THET TELL ALL THE DOCTOR THAT THIS IS A LIFE LINE FOR ALL OF YOUR PATIENTS, JUST GIVE THEM TO THEM AND YOU WILL IN MONEY, TILL THEY DIE, OR THEY CAN'T GET OFF THEM, [ OXYCONTIN ] WE ALL KNOW THAT ONE!!!!!! I SURE. THAT THE WHOLE THING WITH THE MAKER OF DRUGS, AND I DON'T CARE WHO THEY ARE, A=Z